Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.71%
1,092.80
-7.77
-0.71%
—1,100.571,098.941,103.801,084.24——
SIXC
Communications
SIXC
Communications
SIXC
-0.07%
604.74
-0.41
-0.07%
—605.15605.15606.69602.76——
SIXE
Energy
SIXE
Energy
SIXE
+1.64%
1,214.80
+19.61
+1.64%
—1,195.191,204.711,221.691,204.71——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,724.57
-15.34
-0.88%
—1,739.911,734.501,734.501,710.67——
SIXM
Financials
SIXM
Financials
SIXM
+0.14%
639.43
+0.87
+0.14%
—638.56640.21645.32638.69——
SIXR
Staples
SIXR
Staples
SIXR
+0.91%
839.15
+7.58
+0.91%
—831.57840.48844.16834.54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.06%
215.62
+2.26
+1.06%
—213.36213.36215.79212.77——
SIXT
Technology
SIXT
Technology
SIXT
-1.69%
3,179.52
-54.66
-1.69%
—3,234.183,171.863,195.363,145.46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.13%
936.91
+1.26
+0.13%
—935.65937.31941.44933.16——
SIXV
Health care
SIXV
Health care
SIXV
+0.24%
1,452.77
+3.51
+0.24%
—1,449.261,454.771,462.651,447.95——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,365.18
-17.27
-0.72%
—2,382.452,371.192,380.452,362.86——
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$16.31
-3.38%
(-0.57) 1D
$16.31
0.00% (0.00)
After hours
Closed: Apr 28, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMLX...
Open
$17.05
High
$17.56
Low
$16.11
Mkt. cap
1.81B
Avg. vol.
1.11M
Volume
0.00
52-wk high
$18.60
52-wk low
$4.20
EPS
-$1.53
Beta
-0.22
Shares outstanding
110.54M
No. of employees
136
News stories
From sources across the web
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc
CEO-
Employees136
Founded2013
Headquarters-
SectorPharmaceutical industry
Websiteamylyx.com
Next call in 8 days
Thu, May 7, 8:00 AM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-0.34 est.)USD
Revenue / Estimate
-/ (0.00 est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
22.12M
27.22M
19.86M
21.21M
Cost of revenue
22.12M
27.22M
19.86M
21.21M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.68M
15.64M
16.17M
15.39M
Operating expense
15.68M
15.64M
16.17M
15.39M
Total operating expenses
37.80M
42.86M
36.03M
36.60M
Operating income
-37.80M
-42.86M
-36.03M
-36.60M
Other non operating income
-
-
-
-6.23M
EBT including unusual items
-35.91M
-41.44M
-34.39M
-32.95M
EBT excluding unusual items
-35.91M
-41.44M
-34.39M
-38.48M
Income tax expense
-
-
-
46.00K
Effective tax rate
-
-
-
-0.14%
Other operating expenses
-
-
-
-
Net income
-35.91M
-41.44M
-34.39M
-33.00M
Net profit margin
-
-
-
-
Earnings per share
-0.42
-0.46
-0.37
-0.30
Interest and investment income
2.23M
1.96M
1.82M
3.29M
Interest expense
-
-
-
-
Net interest expenses
2.23M
1.96M
1.82M
3.29M
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.65M
-42.72M
-35.91M
-36.50M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer